MICAL2

Across TCGA pan-cancer cohorts, MICAL2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MICAL2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MICAL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MICAL2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

HNSC, CCRCC, and COAD are the cancer types where MICAL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MICAL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.052	<.001	11	view →
CCRCC	All	III,IV	+0.765	<.001	11	view →
COAD	All	All	+0.189	<.001	8	view →
PDAC	Female	II,III,IV	+0.764	<.001	7	view →
LSCC	All	II,III,IV	−0.328	<.001	6	view →
LUAD	Male	II,III,IV	+0.250	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MICAL2–HNSC

Open the HNSC breakdown →